You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.
Through a startup called FCS Technology, the team is hoping to market the platform for cancer research and, eventually, clinical diagnostic applications.
The groups combined their circulating tumor cell collection and detection platforms to find higher cell numbers in metastatic breast, lung, and melanoma cancer patients.
The firm argues that its tests allows hospitals to expedite patient treatment, while curbing the costs of one-off tests and medication, and minimizing the length of a patient's stay.
Angle's Parsortix yielded lower white blood cell backgrounds in samples, but Biolidics' ClearCell detected melanoma CTCs in additional samples that Parsortix missed.
Consumers have filed complaints about the San Diego-based firm's questionable business practices and lack of response in the last year.
HTG will leverage existing collaborations with firms including Illumina and Thermo Fisher Scientific to continue building in vitro diagnostic assays on their sequencers.
The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.
The team plans to develop an assay that integrates circulating tumor cells and DNA to eliminate the need for repeated imaging surveillance in stage III melanoma patients.
A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.
Undark looks into how coronavirus-related shutdowns are affecting field researchers.
In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.